Desloratadine + Montelukast(Desloratadine + Montelukast) is a medicine used to treat allergies and breathing problems such as allergic rhinitis (seasonal or year-round allergies) and long-term asthma. It contains two medications that work together. Desloratadine helps relieve allergy symptoms like sneezing, itching, and a runny nose without causing drowsiness. Montelukast helps reduce swelling and tightening in the airways, making breathing easier and helping control allergy symptoms over time, especially in people who also have asthma. This combination is usually given when one medicine alone is not enough to prevent strong or long-lasting allergy and asthma symptoms.

Desloratadine + Montelukastaddresses the complex inflammatory pathways involved in chronic allergic disease and asthma, recognising that these conditions are driven by multiple inflammatory mediators, not just histamine.

Desloratadine (Antihistamine) is the active metabolite of loratadine, offering enhanced potency and selectivity. It functions as a highly selective inverse agonist at the peripheral H1 histamine receptor. By occupying these receptors, Desloratadine prevents histamine, the primary mediator of immediate hypersensitivity reactions, from binding to them. This rapidly and effectively suppresses acute allergic symptoms, including urticaria (hives), pruritus (itching), nasal congestion, and watery eyes. Importantly, Desloratadine is categorised as a second-generation (non-sedating) antihistamine because it penetrates the blood-brain barrier poorly, thereby minimising CNS side effects such as drowsiness. The 5mg dose provides complete, 24-hour histamine blockade.

Montelukast (Leukotriene Receptor Antagonist - LTRA) targets a different, equally important pathway. It is a selective and orally active antagonist of the Cysteinyl Leukotriene Receptor Type 1 (CysLT1). Leukotrienes, particularly LTC4, LTD4, and LTE4, are released from mast cells and eosinophils during an allergic response. They are powerful bronchoconstrictors and promote inflammation, mucus secretion, and vascular permeability. By blocking the CysLT1 receptor, Montelukast:

• Reduces bronchial hyperresponsiveness (key to asthma control).

• Inhibits airway inflammation and remodelling.

• Decreases nasal congestion and inflammation over the long term.

The combination is synergistic: Desloratadine provides rapid, powerful relief from immediate, histamine-mediated symptoms, while Montelukast provides long-term, sustained control of the chronic inflammatory components that drive both allergic rhinitis and asthma (the "one airway" concept). The 10mg dose of Montelukast is the standard dose for adult management of asthma and allergic rhinitis.

Desloratadine + Montelukast(Desloratadine 5mg + Montelukast 10mg) is indicated for:

• Symptomatic Relief of Allergic Rhinitis: Specifically for patients with severe, persistent seasonal allergic rhinitis (SAR) or perennial allergic rhinitis (PAR) when symptoms (sneezing, runny nose, nasal congestion, itching) are not adequately controlled by either an antihistamine or an LTRA alone.

• Management of Concomitant Asthma and Allergic Rhinitis: For patients with both conditions, this combination treats allergic symptoms and serves as maintenance therapy for mild-to-moderate persistent asthma.

• Chronic Urticaria (Hives): Treatment of skin manifestations (itchy, raised welts) when a standard antihistamine dose is insufficient.

The combination offers targeted benefits for patients with complex allergic-inflammatory diseases.

The primary benefit is Superior Efficacy in Persistent Symptoms. By targeting both the immediate histamine pathway and the sustained leukotriene pathway, the combination provides more complete relief from the full spectrum of allergic symptoms, particularly nasal congestion, which often responds poorly to antihistamines alone.

It provides Comprehensive Asthma and Allergy Control. This therapy is advantageous for patients with asthma that is triggered or exacerbated by allergic rhinitis, as it simultaneously manages both upper (nasal) and lower (bronchial) airway inflammation.

The therapy boasts a Convenient, Once-Daily Dosing Regimen. The single-tablet combination improves patient adherence compared to taking two separate medications, which is crucial for the effective long-term management of chronic conditions.

Finally, Desloratadine ensures Non-Sedating Relief, allowing patients to maintain their daily activities and cognitive function without the drowsiness associated with first-generation antihistamines.

Side effects are generally mild, but the combination carries a specific Neuropsychiatric Risk associated with Montelukast.

Common Side Effects (Mild and temporary):

• Headache, Dizziness

• Nausea, diarrhoea, or Abdominal pain

• Fatigue, Drowsiness (Minimal, but possible)

• Dry Mouth

Serious Side Effects (Stop taking the medicine and seek urgent medical attention if you experience):

• Neuropsychiatric Events (Montelukast-related): CRITICAL WARNING. New onset or worsening of depression, anxiety, agitation, aggression, abnormal dreams, hallucinations, tremor, or suicidal thoughts or behaviour. Patients must report these changes immediately.

• Severe Allergic Reaction (Anaphylaxis): Rash, swelling of the face, tongue, or throat, or difficulty breathing.

• Liver Problems: Yellowing of the skin or eyes (jaundice), persistent nausea, or pain in the upper right abdomen (Montelukast-related, rare).

• Churg-Strauss Syndrome (Eosinophilic Granulomatosis with Polyangiitis - EGPA): A rare systemic vasculitis sometimes reported in asthma patients taking Montelukast (often during withdrawal from high-dose oral steroids). Symptoms include worsening asthma, flu-like illness, numbness, and severe sinus pain.

• Dosing Schedule: Take one tablet (Desloratadine 5mg + Montelukast 10mg) once daily.

• Timing: Take the tablet at a consistent time each day, preferably in the evening, as Montelukast is often recommended for evening dosing to maximise its effect during nighttime inflammation, and Desloratadine is non-sedating.

• Administration: Swallow the tablet whole with a glass of water. It can be taken with or without food.

• Asthma Management: This medication is for maintenance therapy. It is NOT a rescue inhaler. Do not use it to treat an acute asthma attack.

• Consistency: Take the medication regularly every day, even when symptoms improve, for long-term control of asthma and chronic allergy symptoms.

The efficacy of Desloratadine + Montelukaststems from its dual, non-overlapping antagonistic action on two critical inflammatory pathways.

1. Desloratadine (Histamine Blockade): Acts by binding to the peripheral H1 receptors on effector cells (like smooth muscle, vascular endothelium). This binding competitively inhibits histamine, rapidly reversing the effects of immediate hypersensitivity, such as vasodilation (reducing redness and swelling), increased capillary permeability (reducing fluid/runny nose), and nerve stimulation (reducing itching and sneezing).
2. Montelukast (Leukotriene Blockade): Acts by selectively blocking the CysLT1 receptor. This receptor is primarily activated by LTD4 and is expressed on human airway smooth muscle cells and other pro-inflammatory cells. By blocking CysLT1, Montelukast:

• Prevents bronchoconstriction and airway narrowing.

• Inhibits the proliferation of smooth muscle cells and reduces airway remodelling.

• Decreases the migration and accumulation of inflammatory cells (eosinophils) in the respiratory tract.

The combined inhibition of the H1 and CysLT1 receptors provides a broad spectrum of anti-allergic and anti-inflammatory activity throughout the respiratory system.

• Watch for Mood Changes: The most critical advice is to monitor closely for any changes in mood, behaviour, anxiety, or sleep patterns, especially in the first few weeks. Report these to your doctor immediately.

• Take in the Evening: Taking the dose in the evening is often preferred, as it ensures optimal Montelukast levels during the nighttime hours, when asthma symptoms usually worsen.

• Not a Rescue Drug: Always carry your quick-relief (rescue) inhaler, as this medication will not stop an acute asthma attack.

• Consistency: Take the tablet every day, even if you feel well, to maintain chronic control and prevent flare-ups.

• Temperature: Store Desloratadine + Montelukasttablets at controlled room temperature, typically between 20 °C and 25 °C.
• Protection: Keep the medicine in its original container, protected from excessive heat, light, and especially moisture.
• Safety: Always store securely, out of the reach and sight of children and pets.
• Disposal: Return expired or unused medication to a pharmacy for safe disposal.

• Food Intake: NO INTERACTION. The tablet can be taken with or without food without affecting its absorption or efficacy.

• Alcohol: CAUTION. While Desloratadine is generally non-sedating, the combination may cause minimal drowsiness that is significantly enhanced by alcohol consumption. Limit alcohol intake.

1. CYP3A4 and CYP2C8 Inducers (e.g., Rifampin, Phenytoin): CAUTION. These drugs can significantly increase metabolism and reduce Montelukast's blood concentration, potentially decreasing its therapeutic efficacy.
2. CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin): CAUTION. These drugs may increase the blood concentration of Montelukast, potentially increasing the risk of side effects.
3. Other H1 Antihistamines: CONTRAINDICATED. Do not take other antihistamines (even non-sedating ones) concurrently, as this provides no extra benefit and may increase overall side effects.
4. Oral Corticosteroids: CAUTION. Montelukast can sometimes be introduced when oral steroid doses are being tapered down. Patients must be carefully monitored, particularly for the rare onset of EGPA/Churg-Strauss Syndrome.

• Severe Hepatic Impairment: CAUTION. Montelukast clearance is reduced. Patients with pre-existing severe liver disease require careful monitoring.

• Acute Asthma: CONTRAINDICATED. The drug is for maintenance therapy; it is ineffective and inappropriate for treating status asthmaticus or acute asthma exacerbations.

• Known Sensitivity: CONTRAINDICATED in patients with known hypersensitivity to Desloratadine, Loratadine, Montelukast, or any component of the formulation.

The standard daily dose is one tablet containing Desloratadine 5mg and Montelukast 10mg, once daily. This dose provides the maximum recommended daily maintenance dose for each component for treating adults with chronic allergic rhinitis and asthma. Consistency is essential for sustained therapeutic control.

Symptoms of overdose are generally mild, including abdominal pain, somnolence (Montelukast), headache, and dry mouth (Desloratadine). However, severe overdose, though rare, could lead to tachycardia, psychosis, or severe gastrointestinal distress. There is no specific antidote. Treatment is symptomatic and supportive, focusing on standard measures to remove unabsorbed drug (gastric lavage, activated charcoal) and monitoring vital signs. If an overdose is suspected, seek emergency medical help immediately.

Since this is a daily maintenance drug, consistency is essential.

• Missed Dose: If you miss your scheduled dose, take it as soon as you remember.

• Near Next Dose: If it is almost time for your next scheduled dose (e.g., within 8-12 hours of it), skip the missed dose entirely.

• Do Not Double Dose: Never take two tablets to compensate for a forgotten one. Resume your regular one-tablet daily dosing schedule.

• Contact your doctor if you frequently miss doses.